Hemostasis and Tissue Sealing Agents Market to Exhibit 8.1% Cagr Till 2028 : Johnson & Johnson, C R Bard, Integra Life Sciences, Etc

New York, NY -- (SBWire) -- 04/22/2021 --The Global Hemostasis and Tissue Sealing Agents Market was valued at USD 3.63 billion in 2018 and is expected to reach USD 6.76 billion by the year 2026, at a CAGR of 8.1%. Blood loss has always been a concern in surgery. Hemostasis is the formation of blood clots at the site of injury. It is a complex interaction between the platelets plasma proteins and coagulation and fibrinolysis pathways. Platelets provide the initial hemostasis response.

The number of hemostatic agents and tissue sealants have been developed and are currently used in various surgical disciplines all across the world. Hemostasis and tissue sealing agents are used in medical applications and act as a catalyst in blood clotting. This reduces the time required for clotting of the blood and prevents blood loss. An increase in the adoption of advanced technologies and increasing investment in the healthcare infrastructure is expected to drive the market growth in the coming decades. Additionally, the increasing number of diabetic patients, cardiovascular conditions, urological issues, liver problems, and gastrointestinal conditions owing to the changed lifestyle and inappropriate eating habits among the population is expected to raise the number of surgeries. For instance, according to the CDC, these procedures categories made up 72% of procedures performed on females and 67% of those performed on males. It is anticipated to drive the market growth positively for hemostasis and tissue sealing products in the market during the forecast period.

Some of the critical factors responsible for propelling the growth of the Hemostasis and tissue sealing market include increasing need to stop the blood during surgical processes, reduction in blood loss, increased demand for surgeries owing to an increase in chronic disease patients, and an increasing number of road accidents. For instance, according to the WHO, every year approximately 1.35 million people are cut short as a result of a road traffic crash, between 20 and 50 million more people suffer non-fatal injuries, with many incurring a disability as a result of their injury. Additionally, hemostasis and tissue sealants also help in the healing of the damage. It facilitates healing of the injury ranging from a small cut to serious neurological surgery. However, complications can include allergic reactions and other post-surgery implications, associated side effects, and an increase in surgical processes coupled with high product prices are expected to hinder the market growth during the forecast period.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2257

Further key findings from the report suggest:
Hemostasis and Tissue Sealing Agents market is growing at a CAGR of 9% in Asia Pacific followed by North America and Europe, with 8.1 % and 8.0 % CAGR, respectively. Increased demand of hemostats and tissue sealants in the surgical processes is driving the growth of the market.

In 2018, Topical Hemostats segment is expected to dominate Hemostasis and Tissue Sealing Agents which holds 51.3% of the global market. North America regional market is the chief revenue generating source for this product segment, followed by European countries and Asia-Pacific regions

Chronic diseases like Diabetes, Hernia fixation, urological disorders, spinal injuries, brain hemorrhage and liver injuries are few diseases that require the usage of hemostats and tissue sealing products. Increase in these diseases will ultimately lead to an increase in demand for tissue sealants. For instance, a new 'biological glue' developed by Chinese researchers could one day stop hearts and arteries from uncontrollably bleeding.

Increased preference of hemostats and tissue sealants over the other products for the process of injury healing or wound closure has led to its increasing use in multiple conditions, especially in endoscopic procedures.

Minimally invasive surgery is making use of hemostasis and tissue sealing products for urological treatments, thereby promoting the growth of Hemostasis and tissue sealing market. For instance, in June 2019, FDA clears J&J and Grifols' blood-stopping protein spray for surgical bleeds

The highest demand is expected from the cardiovascular conditions followed by general surgeries. For instance, according to the data of National Center for Health Statistics, 48 million surgical inpatient procedures were performed in the United States

Owing to the better results obtained by using hemostasis and tissue sealing products in cardiovascular surgeries and general surgeries has attributed to an increased demand for tissue sealing products.

Topical hemostat is extensively used in general injury treatment and provides cost efficiency, quick and easy absorbability, minimal tissue reaction and non-antigenicity owing to the larger share of the market by topical hemostats segment.

Hemostasis includes the coagulation of blood vessels, fibrinolysis and platelet aggregation pathways by activation of hemostasis system. Hemostats involve hemostasis agents and their delivering medium which could be ready-to-use applicator or a pre-filled syringe.

Some of the prime advantages associated with tissue sealants are, ease of use, better visualization, reduced need for transfusion, better application in patients with coagulation disorders, reduced exudates and so on.

Key participants include as Johnson & Johnson, C R Bard, Integra Life Sciences, Cohera Medical, Equimedical, CryoLife, Advance Medical, Solution, Smith & Nephew, Pfizer, and B Braun Medical Inc.

For the purpose of this report, Reports and Data has segmented the Hemostasis and Tissue Sealing Agents market on the basis of type, material type, application type, end use, and region:

Type (Revenue, USD Million; 2016–2026)
Topical Hemostats
Adhesives & Tissue sealants
Others

Material type (Revenue, USD Million; 2016–2026)
Collagen Based
Oxidized Regenerated Cellulose (ORC) based
Gelatin based
Polysaccharide Based
Others

Applications Type (Revenue, USD Million; 2016–2026)
Minimally invasive surgery
General Surgery
Others

End Use (Revenue, USD Million; 2016–2026)
Hospital
Ambulatory Surgical Centers
Home Care Settings
Others

Regional Outlook (Revenue in USD Million; 2016–2026)
North America
S.
Canada
Europe
Germany
France
UK
Spain
Italy
Rest of the Europe
Asia Pacific
China
India
Japan
Rest of Asia-Pacific
Middle East & Africa
Latin America
Brazil

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/2257

The Hemostasis and Tissue Sealing Agents Market research covers a detailed analysis of the following data:
Historical and future growth forecasts of the global Hemostasis and Tissue Sealing Agents Market.
Segmentation of the Hemostasis and Tissue Sealing Agents Market to highlight the growth prospects and trends affecting these segments.
Varying consumption behavior of customers across various regions covered in the report.
Geographical study based on the market share, growth outlook, and key countries.
Agreements, product launches, mergers and acquisitions, and R&D projects of the different key Hemostasis and Tissue Sealing Agents Market players.

Table of Contents
Chapter 1. Market Synopsis
1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique

Chapter 2. Executive Summary
2.1. Summary Snapshot, 2018 – 2026

Chapter 3. Indicative Metrics
3.1. Intensive marketing strategies
3.2. Rapid Development in healthcare infrastructure
3.3. Rapid penetration of major players
3.4. Growing prevalence of chronic disease

Chapter 4. Hemostasis and Tissue Sealing Agents Segmentation & Impact Analysis
4.1. Hemostasis and Tissue Sealing Agents Segmentation Analysis
4.2. Hemostasis and Tissue Sealing Agents Market Value Chain Analysis, 2016-2026
4.3. Regulatory framework
4.4. Hemostasis and Tissue Sealing Agents Market Impact Analysis
4.4.1. Market driver analysis
4.4.1.1. Increase in demand for tissue sealants in surgeries
4.4.1.2. Wide-range of applicability
4.4.2. Market restraint analysis
4.4.2.1. Lack of reimbursement
4.4.2.2. High price of surgical products
4.5. Key opportunities prioritized
4.6. Hemostasis and Tissue Sealing Agents Pricing Analysis
4.7. Industry analysis - Porter's
4.8. Hemostasis and Tissue Sealing Agents PESTEL Analysis

Chapter 5. Hemostasis and Tissue Sealing Agents Market By Product Type Insights & Trends

Continued…..